D8-MMAE (CAT#: ADC-P-008)

ADCs cytotoxin, D8-MMAE(D8-Monomethyl auristatin E; D8-Vedotin) is a deuterated form of MMAE.

Product Information

Description
ADCs cytotoxin, D8-MMAE(D8-Monomethyl auristatin E; D8-Vedotin) is a deuterated form of MMAE.

Classification
Microtubule Inhibitors

Molecular Weight
726.03

Purity
95%

For Research Use Only. NOT FOR CLINICAL USE.

Published Data

+ Submit Publications

Submit a review or a question

Scientific Resources

CAMouse™-Fully Human Antibody Generation Platform

Reviews

Literature

Protocol

Customer Reviews and FAQs

There are currently no Customer reviews or questions for ADC-P-008. Click the button above to contact us or submit your feedback about this product.

Customer Reviews FAQ

Excellent

The D8-MMAE cytotoxin delivered exceptional potency in our ADC projects. Its ability to inhibit microtubules was highly effective, providing consistent and reliable results in our cancer research.

Excellent

Excellent product! The D8-MMAE from Creative Biolabs worked flawlessly in our experiments, offering strong microtubule inhibition and targeted cytotoxicity. It's a valuable tool for ADC development.

Excellent

Highly effective! The deuterated form of MMAE, D8-MMAE, provided enhanced stability and potency in our studies. Its performance in inhibiting microtubules was impressive, advancing our therapeutic research.

Excellent

Impressive results! The D8-MMAE cytotoxin demonstrated strong efficacy in our lab. The microtubule inhibition was particularly potent, making it an essential component in our ADC formulations.

Excellent

Very satisfied with the D8-MMAE product. Its microtubule inhibitory action was robust, providing the consistent cytotoxicity we needed for our research. Highly recommended for anyone working on ADCs.

Q: 1: What is D8-MMAE, and how is it used in antibody-drug conjugates?
A: D8-MMAE (D8-Monomethyl auristatin E; D8-Vedotin) is a deuterated form of the cytotoxin MMAE, commonly used in ADCs. It functions as a microtubule inhibitor, disrupting cell division and inducing apoptosis in cancer cells, making it a powerful component in targeted cancer therapies.
Q: 2: How does D8-MMAE differ from standard MMAE?
A: D8-MMAE is a deuterated form of MMAE, meaning that some of the hydrogen atoms in the molecule have been replaced with deuterium, a heavier isotope of hydrogen. This modification can enhance the stability and pharmacokinetics of the molecule, potentially improving its therapeutic profile compared to standard MMAE.
Q: 3: What are the advantages of using D8-MMAE as a cytotoxin in ADCs?
A: The deuteration of D8-MMAE can lead to improved metabolic stability, reduced clearance, and potentially enhanced efficacy compared to non-deuterated MMAE. These advantages make D8-MMAE a valuable cytotoxin for use in ADCs aimed at targeting cancer cells more effectively and with fewer side effects.
Q: 4: What types of cancer cells are most responsive to ADCs containing D8-MMAE?
A: ADCs containing D8-MMAE are particularly effective against cancer cells that are sensitive to microtubule inhibition. This includes a wide range of solid tumors and hematological malignancies, where the disruption of microtubule dynamics can effectively halt cell division and induce apoptosis.
Q: 5: How does Creative Biolabs support researchers in the development of ADCs using D8-MMAE?
A: Creative Biolabs offers comprehensive support for researchers developing ADCs using D8-MMAE, including technical consultation, custom synthesis, and optimization services. They provide guidance on conjugation methods, cytotoxicity testing, and stability assessments to ensure the success of ADC projects.

Quick Links

ADC Toxins

Drug-linker Complexes

Customized ADCs

Anti-Ab ADCs

Online Inquiry

Welcome! For price inquiries, please feel free to contact us through the form on the left side. We will get back to you as soon as possible.